The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Akt-regulated pathways in prostate cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationPten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“…Hif1a stabilization may play an important role downstream in the induction of the neoplastic phenotype in vivo, and that mTOR inhibition, at least in part, reverts aspects of transformation through regulation of Hif1a levels (Hudson et al., 2002; Brugarolas et al., 2004; Majumder et al., 2004).”
BackgroundMechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“In mice lacking both alleles of Pten, PIN develops with earlier onset than in Ptenþ / mice and leads to invasive prostate cancer and ultimately to metastatic cancer (Trotman et al., 2003; Wang et al., 2003).”
BackgroundEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Self-citationMutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
Does the ribosome translate cancer?
Ruggero, D., & Pandolfi, P. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1015 · Cited by 928
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R., & Tonks, N. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9052 · Cited by 775
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1735 · Cited by 673
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Germline mutations in PTEN are present in Bannayan-Zonana syndrome
Marsh, D. J., Dahia, P. L. M., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R. J., & Eng, C. (1997) · Nature Genetics · doi:10.1038/ng0897-333 · Cited by 655
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M., & Sellers, W. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2110 · Cited by 575
Self-citationInsulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study
Wolk, A., Mantzoros, C. S., Andersson, S.-O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H.-O., & Trichopoulos, D. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.911 · Cited by 575
Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8969-8982.2000 · Cited by 570
Self-citationAn inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L., & Van Obberghen, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204152200 · Cited by 539
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Self-citationAllosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.011 · Cited by 503
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Peterson, R. T., Desai, B. N., Hardwick, J. S., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4438 · Cited by 486
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease
Nelen, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1383 · Cited by 464
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., Witte, O., Said, J., Loda, M., & Reiter, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203426 · Cited by 436
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Xu, J., Zheng, S. L., Komiya, A., Mychaleckyj, J. C., Isaacs, S. D., Hu, J. J., Sterling, D., Lange, E. M., Hawkins, G. A., Turner, A., et al. (2002) · Nature Genetics · doi:10.1038/ng994 · Cited by 392
Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene
Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Sun, H., Liu, X., & Wu, H. (2002) · genesis · doi:10.1002/gene.10036 · Cited by 386
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
Self-citationRuggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., & Ghosh, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
Casey, G., Neville, P. J., Plummer, S. J., Xiang, Y., Krumroy, L. M., Klein, E. A., Catalona, W. J., Nupponen, N., Carpten, J. D., Trent, J. M., et al. (2002) · Nature Genetics · doi:10.1038/ng1021 · Cited by 305
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
Aoki, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011528498 · Cited by 303
Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3192 · Cited by 299
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232229100 · Cited by 285
Self-citationCoppola, D., Ferber, A., Miura, M., Sell, C., D'Ambrosio, C., Rubin, R., & Baserga, R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4588 · Cited by 284
DiGiovanni, J., Kiguchi, K., Frijhoff, A., Wilker, E., Bol, D. K., Beltrán, L., Moats, S., Ramirez, A., Jorcano, J., & Conti, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3455 · Cited by 281
Lynch, E. D., Ostermeyer, E. A., Lee, M. K., Arena, J. F., Ji, H., Dann, J., Swisshelm, K., Suchard, D., MacLeod, P. M., Kvinnsland, S., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/301639 · Cited by 276
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
Tsao, H., Zhang, X., Benoit, E., & Haluska, F. G. (1998) · Oncogene · doi:10.1038/sj.onc.1201881 · Cited by 243
Rökman, A., Ikonen, T., Seppälä, E. H., Nupponen, N., Autio, V., Mononen, N., Bailey-Wilson, J., Trent, J., Carpten, J., Matikainen, M. P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340450 · Cited by 238
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0005 · Cited by 232
Cheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Ma, X., Ziel-van der Made, A. C., Autar, B., van der Korput, H. A., Vermeij, M., van Duijn, P., Cleutjens, K. B., de Krijger, R., Krimpenfort, P., Berns, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4519 · Cited by 191
Warshamana-Greene, G. S., Litz, J., Buchdunger, E., García-Echeverría, C., Hofmann, F., & Krystal, G. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1544 · Cited by 184
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillón, D. H., Bastian, B. C., O’Hagan, R. C., Bosenberg, M., Parsons, R. E., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 171
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
Backman, S. A., Ghazarian, D., So, K., Sanchez, O., Wagner, K.-U., Hennighausen, L., Suzuki, A., Tsao, M.-S., Chapman, W. B., Stambolic, V., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308217100 · Cited by 159
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN
Gray, I., Stewart, L., Phillips, S. M. A., Hamilton, J., Gray, N. E., Watson, G., Spurr, N., & Snary, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.674 · Cited by 154
Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors
Ward, S. G., Sotsios, Y., Dowden, J., Bruce, I., & Finan, P. M. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00048-6 · Cited by 139
Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis
Stiles, B. L., Gilman, V., Khanzenzon, N., Lesche, R., Li, A., Qiao, R., Liu, X. Z., & Wu, H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3842-3851.2002 · Cited by 139
de Sande, T. V., Roskams, T., Lerut, E., Joniau, S., Poppel, H. V., Verhoeven, G., & Swinnen, J. V. (2005) · The Journal of Pathology · doi:10.1002/path.1760 · Cited by 136
Rennert, H., Bercovich, D., Hubert, A., Abeliovich, D., Rozovski, U., Bar‐Shira, A., Soloviov, S., Schreiber, L., Matzkin, H., Rennert, G., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342775 · Cited by 128
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer
Liao, Y., Grobholz, R., Abel, U. R., Trojan, L., Michel, M. S., Angel, P. E., & Mayer, D. (2003) · International Journal of Cancer · doi:10.1002/ijc.11471 · Cited by 127
Miwa, W., Yasuda, J., Murakami, Y., Yashima, K., Sugano, K., Sekine, T., Kono, A., Egawa, S., Yamaguchi, K. D., Hayashizaki, Y., et al. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1280 · Cited by 123
A critical role for p27 kip1 gene dosage in a mouse model of prostate carcinogenesis
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Borowsky, A. D., Lin, Y., Kim, M., Lee, H., Shih, W. J., Cardiff, R. D., Shen, M. M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407693101 · Cited by 123
Ma, L., Teruya‐Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon‐Cardo, C., & Pandolfi, P. P. (2005) · Genes & Development · doi:10.1101/gad.1314405 · Cited by 121
Ruan, W., Powell-Braxton, L., Kopchick, J. J., & Kleinberg, D. L. (1999) · Endocrinology · doi:10.1210/endo.140.5.6721 · Cited by 113
Xu, J., Zheng, S. L., Carpten, J. D., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/319513 · Cited by 110
Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90
Chiosis, G., Lucas, B. S., Huezo, H., Solit, D. B., Basso, A., & Rosen, N. X. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481778 · Cited by 106
PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate
Dong, J., Sipe, T. W., Hyytinen, E., Li, C., Heise, C. E., McClintock, D. E., Grant, C. D., Chung, L. W. K., & Frierson, H. F. (1998) · Oncogene · doi:10.1038/sj.onc.1202119 · Cited by 100
mTOR as a Positive Regulator of Tumor Cell Responses to Hypoxia
Abraham, R. T. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_18 · Cited by 98
Amplification of 19q13.1–q13.2 sequences in ovarian cancer
Thompson, F. H., Nelson, M. A., Trent, J. M., Guan, X., Liu, Y., Yang, J.-M., Emerson, J., Adair, L., Wymer, J. A., Balfour, C. A., et al. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00248-0 · Cited by 96
Prostate cancer : principles and practice
Kantoff, P. W., Carroll, P. R., D'Amico, A. V., Ross, R. K., Isaacs, J. T., & Scher, H. I. (2002) · Cited by 71
Prostate Cancer: Principles and Practice
Cathelineau, X. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg276 · Cited by 60
Luo, J., Sobkiw, C. L., Logsdon, N. M., Watt, J. M., Signoretti, S., O’Connell, F., Shin, E., Shim, Y., Pao, L. I., Neel, B. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504378102 · Cited by 58
In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316
Meuillet, E. J., Ihle, N. T., Baker, A. F., Gard, J. M. C., Stamper, C., Williams, R. R., Coon, A., Mahadevan, D., George, B. L., Kirkpatrick, L., et al. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040042380487 · Cited by 54
Gills, J. J., & Dennis, P. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.7.787 · Cited by 46
Tabellini, G., Tazzari, P. L., Bortul, R., Billi, A. M., Conte, R., Manzoli, L., Cocco, L., & Martelli, A. M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05073.x · Cited by 24
Eaton, S. R., Cody, W. L., Doherty, A. M., Holland, D. R., Panek, R. L., Lu, G. H., Dahring, T. K., & Rose, D. R. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9802766 · Cited by 14
Cited by
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
Metadata
- Authors
- Majumder, P. K., & Sellers, W. R.
- Venue
- Oncogene
- Published
- 2005-11-14
- Volume
- 24
- Issue
- 50
- Pages
- 7465-7474
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2025319771
- Cited by
- 344
- References
- 97
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.